Young Fatal Case of Familial Hypercholesterolemia: A Case Report
Article Sidebar
Main Article Content
Downloads
Article Details
Copyright (c) 2018 Showkat HI, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Selvan JP, Uthaman B, Abushaban L, Jebaraj R (2007) Homozygous familial hypercholesterolemia with generalized arterial disease. Medical Principle and Practice 16: 75-78. Link: https://goo.gl/kb2aFB
Mabuchi H, Tatami R, Haba T, Ueda K, Ueda R, et al. (1978) Homozygous familial hypercholesterolaemia in Japan. Amer J Med 65: 290-297. Link: https://goo.gl/63kzS6
Rader DJ, Hobbs HH (2008) Disorders of lipoprotein metabolism. Harrison Principles of Internal Medicine 2: 2416-2429. Link: https://goo.gl/Yph7gc
Nemati MH, Astaneh B (2010) Optimal management of familial hypercholesterolemia: treatment and management strategies. Vascular Health and Risk Management 6: 1079-1088. Link: https://goo.gl/Czws9H
(2008) National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. Clinical Guidelines 71:. Link: https://goo.gl/1Lwgfn
Catapano AL, Reiner Z, Backer GD, Graham I, Wiklnd O, et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217: 1-44. Link: https://goo.gl/EoWd1E
Wolff K, Johnson RA, Suurmond R (2005) Fitzpatrick’s Color Atlas & Synopsis of Clinical Dermatology, Edn 5. McGraw-Hill Medical Publishing Division. Link: https://goo.gl/1XRX2W
Palacio CH, Harring TR, Nguyen NTT, Goss JA, O’Mahony CA (2011) Homozygous familial hypercholesterolemia: case series and review of the literature. Case Rep Transplant. Link: https://goo.gl/E9rdRR
(2008) NICE Clinical Guidelines: Identification and management of familial hypercholesterolaemia. London: Royal College of General Practitioners 2008 71. Link: https://goo.gl/jrfBY4
Sonnett T, Robinson J, Milani P, Campbell RK (2010) Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children. Adolesc Health Med Ther 1: 53–60. Link: https://goo.gl/nnFM6D
Ohshito T, Shimabukuro T, Sunagawa M, Ohta T (2009) An 11-year-old boy with familial hypercholesterolemia showing multiple xanthomas and advanced atherosclerosis, who responded to lipid-lowering therapy using statin. J Atheroscler Thromb 16: 698-701. Link: https://goo.gl/MW7Xss